The Interplay of Microbiota and Polyomaviruses in Human Health and Disease

A special issue of Pathogens (ISSN 2076-0817).

Deadline for manuscript submissions: 25 August 2025 | Viewed by 1160

Special Issue Editor


E-Mail Website
Guest Editor
Department of Public Health and Infectious Diseases, “Sapienza” University, 00185 Rome, Italy
Interests: human polyomaviruses; Merkel cell polyomavirus; oncogenesis; microRNAs; DNA damage response
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is currently recognized that viral infections and changes in the composition of microbiota can contribute to the development of human diseases. Human polyomaviruses (HPyVs) are small non-enveloped DNA viruses widely distributed among the population. Following initial asymptomatic infection, HPyVs establish a lifelong persistence as part of the body microbiota, with low levels of replication and shedding. However, in immunocompromised conditions, viral reactivation can occur, posing a significant pathogenic treat. JC, BK and Merkel Cell polyomaviruses (JCPyV, BKPyV, MCPyV) are well known to be disease-associated. In particular, MCPyV is the only one responsible for human cancer. It is significant to note that infections with these viruses do not necessarily lead to disease, but they can be one of many contributing factors to pathogenesis. Virus-associated diseases generally develop as part of persistent infection over many years. In this context, the dynamic interactions among latent/persistent HPyVs infection and other components of microbiota may be crucial for the onset of various human diseases. Understanding these relationships may contribute towards identifying diagnostic and prognostic markers or pathways to recognize or characterize virus-associated disorders early. In this Special Issue, we intend to explore some aspects to better understand the interplay within HPyVs and microbiota and its contribution to human diseases. Studies on cellular pathways altered by these interactions and potentially involved in disease progression are welcome.

Dr. Valeria Pietropaolo
Guest Editor

We extend our sincere appreciation to Dr. Sara Passerini of "Sapienza" University for her noteworthy contributions to the special issue.

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • human polyomaviruses (HPyVs)
  • microbiota
  • co-infection patterns
  • cancer
  • diagnostic markers
  • cellular pathways
  • immunosuppression

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

13 pages, 3282 KiB  
Review
Merkel Cell Polyomavirus Co-Infection in HIV/AIDS Individuals: Clinical Diagnosis, Consequences and Treatments
by Xianfeng Zhou, Chenxue Yin, Ziqi Lin, Zhangren Yan and Jiangang Wang
Pathogens 2025, 14(2), 134; https://doi.org/10.3390/pathogens14020134 - 2 Feb 2025
Viewed by 909
Abstract
Merkel cell polyomavirus (MCV) was named for its role as the causative agent of Merkel cell carcinoma (MCC), which is MCV positive in approximately 80% of cases. MCV is classified as a Group 2A carcinogen, which promotes carcinogenesis by integrating T-antigen into the [...] Read more.
Merkel cell polyomavirus (MCV) was named for its role as the causative agent of Merkel cell carcinoma (MCC), which is MCV positive in approximately 80% of cases. MCV is classified as a Group 2A carcinogen, which promotes carcinogenesis by integrating T-antigen into the cell genome. The prevalence of anti-MCV antibodies in the general population can be as high as 90%. MCV typically promotes cancer by integrating T-antigen genes into the host cell genome, and 80% of MCC cases are attributed to MCV activation. In immunocompetent individuals, MCV usually remains latent after infection. However, the incidence of MCC increases significantly in immunocompromised or immunodeficient patients, such as those who have undergone organ transplantation, have chronic lymphocytic leukemia, or are living with human immunodeficiency virus (HIV) infection. Acquired immunodeficiency is a particular feature of people living with HIV. Currently, research on HIV/AIDS patients with MCV infection, clinical outcomes, and treatments is quite limited. This paper reviews previous research and systematically examines the relationship between HIV/AIDS and MCV-associated diseases, with the aim of providing valuable information for the prevention, diagnosis, and treatment of MCV in vulnerable populations. Full article
Show Figures

Figure 1

Back to TopTop